223 related articles for article (PubMed ID: 19933807)
1. Voriconazole pharmacokinetics in liver transplant recipients.
Johnson HJ; Han K; Capitano B; Blisard D; Husain S; Linden PK; Marcos A; Kwak EJ; Potoski B; Paterson DL; Romkes M; Venkataramanan R
Antimicrob Agents Chemother; 2010 Feb; 54(2):852-9. PubMed ID: 19933807
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.
Han K; Capitano B; Bies R; Potoski BA; Husain S; Gilbert S; Paterson DL; McCurry K; Venkataramanan R
Antimicrob Agents Chemother; 2010 Oct; 54(10):4424-31. PubMed ID: 20679503
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.
Han K; Bies R; Johnson H; Capitano B; Venkataramanan R
Clin Pharmacokinet; 2011 Mar; 50(3):201-14. PubMed ID: 21294597
[TBL] [Abstract][Full Text] [Related]
4. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
6. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
[TBL] [Abstract][Full Text] [Related]
11. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of voriconazole in adults.
Hope WW
Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F
J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725
[TBL] [Abstract][Full Text] [Related]
15. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
16. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
17. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A; Nieth V; Calandra T; Bille J; Bolay S; Decosterd LA; Buclin T; Majcherczyk PA; Sanglard D; Marchetti O
Antimicrob Agents Chemother; 2007 Jan; 51(1):137-43. PubMed ID: 17088483
[TBL] [Abstract][Full Text] [Related]
18. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.
Romero AJ; Le Pogamp P; Nilsson LG; Wood N
Clin Pharmacol Ther; 2002 Apr; 71(4):226-34. PubMed ID: 11956505
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
